Furthermore, we choosed pAKT inhibitor(LY294002) and p-p38MAPK inhibitor (SB203580) to treat NSCLC cell line and finally found that ERβ/MMP-2 was significantly abrogated when pAKT and p-p38MAPK was suppressed. This evidence concerns the gene MMP2 and non-small cell lung carcinoma.